News.
Politico Features Addition of Former Congressman Ed Perlmutter as NCR Policy Advisor
PERLMUTTER JOINS NATIONAL CANNABIS ROUNDTABLE — Industry group National Cannabis Roundtable is adding a major player to its ranks: former Rep. Ed Perlmutter (D-Colo.), the long-time champion of the cannabis banking bill, is joining NCR as a policy adviser. “When I retired from Congress, I made it clear that I remained as committed as ever […]
Read More Media Outlets Report on Addition of Former Rep. Ed Perlmutter to NCR Policy Leadership Team
Read full coverage from MMJ Daily, Cannabis Business Times, Green Market Report, Marijuana Moment, and Cannabis Wire.
Read More Marijuana Moment Highlights The National Cannabis Roundtable’s New Member Companies.
Read full coverage here.
Read More Media Outlets Showcase Newest NCR Members Ascend Wellness Holdings, Proper Brands, and Verano.
Read full coverage from Cannabis Business Times, MMJ Daily, Politico Pro, and Cannabis Wire.
Read More NCR Interviewed for Vangst Podcast, \”Proud to Work in Cannabis\”
NCR\’s Executive Director Saphira Galoob, Director of Policy David Mangone, and Director of Communications and Policy Advisor Erin Moffet sat down with Karson Humiston for an interview for an episode of the Vangst podcast, \”Proud to Work in Cannabis.\” You can find this here, or wherever you listen to podcasts.
Read More NCR Mentioned on High Times: FDA Officials Recommend Reclassifying Pot Under Schedule III, How That Changes Everything
Several organizations and cannabis companies sent statements to High Times. The National Cannabis Roundtable (NCR) applauded the historic acknowledgement that a federal agency has recommended cannabis be reclassified. The NCR announced that they have been instrumental in advocating for and informing the heads of the HHS in a memo, and the DEA in an open letter, as to the scientific […]
Read More NCR Featured on Ganjapreneur: Feds Release Documents Calling for Moving Cannabis to Schedule III
“The importance of a federal agency publicly acknowledging that cannabis is inappropriately classified as a Schedule I substance and has accepted medical use cannot be overstated,” said Saphira Galoob, Executive Director of the National Cannabis Roundtable, in a press release. Read full coverage here.
Read More